Skip to main content

Advertisement

SpringerLink
Log in

Early evaluation of targeted therapy effectiveness in non-small cell lung cancer by dynamic contrast-enhanced CT

  • Research Article
  • Published:
Clinical and Translational Oncology Aims and scope Submit manuscript

Abstract

Purpose

To study the feasibility and clinical value of dynamic contrast-enhanced (DCE) computed tomography (CT) for early evaluation of targeted therapy efficacy in non-small cell lung cancer (NSCLC).

Methods

We measured tumor diameter, peak height (PH), time to peak (TP), tumor mass–aortic peak height ratio (M/A), and blood perfusion (BP) in 20 patients with advanced NSCLC using DCE-CT before and 7 days after treatment. Therapy efficacy was assessed with conventional CT 4–6 weeks post-treatment.

Results

Patients were grouped into those with partial response (PR), stable disease (SD), and progressive disease (PD) according to the therapy efficacy assessment at 4–6 weeks post-treatment. The PR group primary tumor diameter (P = 0.0007) and BP (P = 0.0225) were reduced at 7 days post-treatment; the SD group DCE-CT value changes were not significant. The PD group M/A (P = 0.0443) and BP (P = 0.0268) were increased 7 days post-treatment. The BP decrease group had significantly longer progression-free survival than the BP increase group (median, 54 vs. 6 weeks).

Conclusion

DCE-CT can evaluate targeted therapy efficacy at 7 days post-treatment. Decreased primary tumor diameter and BP indicate tumor sensitivity to therapy; increased BP with unchanged tumor diameter suggests the tumor is not sensitive to therapy. Reduced BP suggests treatment effectiveness.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96.

    Article  PubMed  Google Scholar 

  2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med. 2002;346:92–8.

    Article  PubMed  CAS  Google Scholar 

  3. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomized, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527–37.

    Article  PubMed  CAS  Google Scholar 

  4. Satouchi M, Negoro S, Funada Y, Urata Y, Shimada T, Yoshimura S, et al. Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib. Br J Cancer. 2007;96:1191–6.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  5. Scagliotti G, Govindan R. Targeting angiogenesis with multitargeted tyrosine kinase inhibitors in the treatment of non-small cell lung cancer. Oncologist. 2010;15:436–46.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  6. Zhao B, James LP, Moskowitz CS, Guo P, Ginsberg MS, Lefkowitz RA, et al. Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology. 2009;252:263–72.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Colombi D, Di Lauro E, Silva M, Manna C, Rossi C, De Filippo M, et al. Non-small cell lung cancer after surgery and chemoradiotherapy: follow-up and response assessment. Diagn Interv Radiol. 2013;19:447–56.

    PubMed  Google Scholar 

  8. Fraioli F, Anzidei M, Zaccagna F, Mennini ML, Serra G, Gori B, et al. Whole-tumor perfusion CT in patients with advanced lung adenocarcinoma treated with conventional and antiangiogenic chemotherapy: initial experience. Radiology. 2011;259:574–82.

    Article  PubMed  Google Scholar 

  9. Liu-Jarin X, Stoopler MB, Raftopoulos H, Ginsburg M, Gorenstein L, Borczuk AC. Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy. Mod Pathol. 2003;16:1102–8.

    Article  PubMed  Google Scholar 

  10. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med. 2009;50:122S–50S.

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Ng QS, Goh V, Fichte H, Klotz E, Fernie P, Saunders MI, et al. Lung cancer perfusion at multi-detector row CT: reproducibility of whole tumor quantitative measurements. Radiology. 2006;239:547–53.

    Article  PubMed  Google Scholar 

  12. Wang J, Wu N, Cham MD, Song Y. Tumor response in patients with advanced non–small cell lung cancer: perfusion ct evaluation of chemotherapy and radiation therapy. AJR Am J Roentgenol. 2009;193:1090–6.

    Article  PubMed  Google Scholar 

  13. Lind JS, Meijerink MR, Dingemans AM, van Kuijk C, Ollers MC, de Ruysscher D, et al. Dynamic contrast-enhanced CT in patients treated with sorafenib and erlotinib for non-small cell lung cancer: a new method of monitoring treatment? Eur Radiol. 2010;20:2890–8.

    Article  PubMed  PubMed Central  Google Scholar 

  14. Erasmus JJ, Gladish GW, Roemeling L, Sabloff BS, Truong MT, Herbst RS, et al. Inter-observer and intra-observer variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol. 2003;21:2574–82.

    Article  PubMed  Google Scholar 

  15. Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, et al. Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer. J Clin Oncol. 2011;29:3316–21.

    Article  PubMed  CAS  Google Scholar 

  16. Yabuuchi H, Hatakenaka M, Takayama K, Matsuo Y, Sunami S, Kamitani T, et al. Non-small cell lung cancer: detection of early response to chemotherapy by using contrast-enhanced dynamic and diffusion-weighted MR imaging. Radiology. 2011;261:598–604.

    Article  PubMed  Google Scholar 

  17. Usmanij EA, de Geus-Oei LF, Troost EG, Peters-Bax L, van der Heijden EH, Kaanders JH, et al. 18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy. J Nucl Med. 2013;54:1528–34.

    Article  PubMed  CAS  Google Scholar 

  18. Lu S, Li ZM. Targeted therapy of lung cancer-data from Asia. China Oncology. 2007;17:8–13.

    CAS  Google Scholar 

  19. Tacelli N, Santangelo T, Scherpereel A, Duhamel A, Deken V, Klotz E, et al. Perfusion CT allows prediction of therapy response in non-small cell lung cancer treated with conventional and anti-angiogenic chemotherapy. Eur Radiol. 2013;23:2127–36.

    Article  PubMed  Google Scholar 

  20. Tognolini A, Schor-Bardach R, Pianykh OS, Wilcox CJ, Raptopoulos V, Goldberg SN. Body tumor CT perfusion protocols: optimization of acquisition scan parameters in a rat tumor model. Radiology. 2009;251:712–20.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science. 2005;307:58–62.

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This work was supported by a grant from the Capital Medical Development Research Foundation of China.

Author information

Authors and Affiliations

  1. Department of Radiology, Affiliated Hospital of Academy of Military Medical Sciences, #8 Fengtai dong street, Fengtai District, Beijing, 100071, China

    P.-G. Qiao, H.-T. Zhang, J. Zhou, M. Li, J.-L. Ma, N. Tian, X.-D. Xing & G.-J. Li

Authors
  1. P.-G. Qiao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. H.-T. Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J.-L. Ma
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N. Tian
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. X.-D. Xing
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. G.-J. Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G.-J. Li.

Ethics declarations

There is no conflict of interest in publishing this manuscript.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Qiao, PG., Zhang, HT., Zhou, J. et al. Early evaluation of targeted therapy effectiveness in non-small cell lung cancer by dynamic contrast-enhanced CT. Clin Transl Oncol 18, 47–57 (2016). https://doi.org/10.1007/s12094-015-1335-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12094-015-1335-6

Keywords

Search

Navigation